



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

**Summary for ARTG Entry:** 191034 SOZOL pantoprazole (as sodium sesquihydrate) 20 mg enteric-coated tablet blister pack.

**ARTG entry for** Medicine Registered  
**Sponsor** Apotex Pty Ltd  
**Postal Address** 16 Giffnock Avenue, Macquarie Park, NSW, 2113  
Australia  
**ARTG Start Date** 21/03/2012  
**Product Category** Medicine  
**Status** Active  
**Approval Area** Drug Safety Evaluation Branch

### Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods, and upon the request of the Head, Office of Prescription Medicines Authorisation Branch, Therapeutic Goods Administration, shall produce such evidence to this officer.

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

The therapeutic goods grouped in this registration/listing as export only goods under the following names are included in the Australian Register of Therapeutic Goods and may not be supplied in Australia. Export Name(s) to be added:

### Products

#### 1. SOZOL pantoprazole (as sodium sesquihydrate) 20 mg enteric-coated tablet blister pack.

**Product Type** Single Medicine Product **Effective Date** 6/12/2022

#### Permitted Indications

No Permitted Indications included on Record

#### Indication Requirements

No Indication Requirements included on Record

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

1. For symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) Duodenal ulcer; ii) Gastric ulcer; iii) Gastro-oesophageal reflux disease (GORD): Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD; Reflux oesophagitis; iv) Gastrointestinal lesions refractory H2 blockers; v) Zollinger-Ellison Syndrome. Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.

#### Warnings

See Product Information and Consumer Medicine Information for this product

#### Additional Product information

#### Container information



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

Type	Material	Life Time	Temperature	Closure	Conditions
Blister Pack	Al/Al	2 Years	Store below 25 degrees Celsius	Child resistant closure	Not recorded

#### Pack Size/Poison information

Pack Size	Poison Schedule
100	(S4) Prescription Only Medicine
15	(S4) Prescription Only Medicine
56	(S4) Prescription Only Medicine
60	(S4) Prescription Only Medicine
140	(S4) Prescription Only Medicine
30	(S4) Prescription Only Medicine
5	(S4) Prescription Only Medicine
14	(S4) Prescription Only Medicine
50	(S4) Prescription Only Medicine
28	(S4) Prescription Only Medicine

#### Components

1 .

Dosage Form	Tablet, enteric coated
Route of Administration	Oral
Visual Identification	Yellow, oval, biconvex enteric-coated tablets, plain on both sides.

#### Active Ingredients

pantoprazole sodium sesquihydrate	22.7 mg
Equivalent: pantoprazole	20 mg

#### Other Ingredients (Excipients)

calcium stearate  
colloidal anhydrous silica  
crospovidone  
hypromellose  
iron oxide yellow  
lecithin  
macrogol 6000  
mannitol  
methacrylic acid copolymer  
polysorbate 80  
polyvinyl alcohol  
purified talc  
purified water  
sodium carbonate  
sodium hydroxide  
sodium lauryl sulfate  
sodium starch glycollate  
titanium dioxide  
xanthan gum

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.